ARQT

Arcus Biosciences (ARQT) is the lead sponsor of 10 active clinical trials listed on ClinicalTrials.gov^[4], including 3 Phase 3^[1], 2 Phase 2^[2], 5 Phase 1^[3].

Trial NCT05568095^[5] evaluates Domvanalimab in Advanced Upper Gastrointestinal Tract Adenocarcinoma with a target enrollment of 1040 participants. Trial NCT07011719^[6] evaluates Casdatifan in Metastatic Clear Cell Renal Cell Carcinoma with a target enrollment of 720 participants. Trial NCT06608927^[7] evaluates Quemliclustat in Metastatic Pancreatic Ductal Adenocarcinoma with a target enrollment of 610 participants.

ARQT has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[8].